Taylor Brooks
If you have ADHD, or you’re the parent of a child who does, you’ve probably already seen the headlines. The FDA approved a new ADHD medication called Simtriyo (centanafadine) on July 24, 2026, and for once, the excitement feels warranted. This isn’t another stimulant with a slightly different delivery system. It’s a genuinely new class of drug, the first-ever norepinephrine, dopamine, and serotonin reuptake inhibitor approved for ADHD, and it works on brain chemistry in a way nothing before it has. If you’ve been through the stimulant carousel, or watched your kid struggle with anxiety on top of ADHD and felt like the medication options were a bad menu, this news might hit differently.
But you might be wondering: what does this actually mean for you, right now, this August? And here’s the honest answer: it means something real, but probably not as quickly as you’d hope. Simtriyo hasn’t reached pharmacy shelves yet. It’s waiting on DEA scheduling, a process that typically takes up to three months, and where it lands on that schedule could significantly shape how easy it is to get. In the meantime, people are asking smart questions. Does a new mechanism mean medication works better? Does a better medication mean therapy matters less? The short answer to both is complicated, and worth slowing down for.
According to Otsuka’s official approval announcement, ADHD affects approximately 22.5 million children, adolescents, and adults in the U.S. That’s a lot of people who’ve been managing with tools that work imperfectly, at best. What centanafadine brings to the table, at least on paper, is a legitimately different angle of attack.
- Simtriyo (centanafadine) was FDA-approved July 24, 2026 , the first NDSRI approved for ADHD.
- It's approved for adults and children ages 6+ weighing at least 44 lbs, based on four Phase 3 trials.
- Simtriyo is NOT yet available at pharmacies; DEA scheduling could take up to three months.
- Phase 3b data from June 25, 2026 showed positive results in adults with ADHD and comorbid anxiety.
- Medication alone is still insufficient , behavioral therapy remains a necessary part of long-term treatment.
What Makes Simtriyo Actually Different
Most ADHD medications work on one or two neurotransmitters. Stimulants like Adderall and Ritalin primarily boost dopamine and norepinephrine. Strattera, a non-stimulant, targets norepinephrine alone. Simtriyo hits all three: dopamine, norepinephrine, and serotonin. That serotonin piece is what makes this genuinely novel. It’s why the drug’s mechanism gets its own acronym, NDSRI, and why psychiatrists are paying close attention.
Here’s what that difference means in practice: for people whose ADHD comes bundled with anxiety, which is a lot of people, stimulants have always been a calculated risk. They can sharpen focus while also cranking up the anxiety you’re already fighting. Phase 3b trial data released June 25, 2026 showed that centanafadine produced positive results specifically in adults with ADHD and comorbid anxiety, according to reporting in Psychiatric Times. That’s not a minor footnote. That’s a significant portion of the ADHD population who have often been left choosing between managing their attention and managing their nervous system.
The four Phase 3 trials supporting Simtriyo’s approval also showed symptom improvement as early as week one. Fast onset matters. People don’t drop out of treatment if they see results quickly, and early engagement is often what allows behavioral work to take hold.
The Scheduling Question Nobody’s Talking About Enough
Helpful resource: DBT Skills Training Handouts and Worksheets is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)
You might be wondering why a drug approved by the FDA in late July still isn’t available. The DEA has to schedule it separately, and that process can take up to three months. But here’s the part that really matters: whether Simtriyo lands in Schedule II, alongside Adderall and Ritalin, or gets a lower classification could change everything about prescribing and access.
Schedule II drugs come with hard restrictions. No refills, no call-in prescriptions in most states, 30-day limits. If you’ve managed ADHD treatment for yourself or a child for any length of time, you know how much friction those rules create. A non-stimulant NDSRI that earns a lower schedule could become far more accessible in practical terms, especially in areas with stimulant shortages, for patients in certain jobs or situations where a Schedule II prescription creates complications, or for families who simply can’t coordinate the logistics of monthly in-person prescription pickups.
Nobody knows yet where it’ll land. That uncertainty is real, and worth factoring into any conversations with your prescriber right now.
How This Changes (and Doesn’t Change) the Therapy Question
Here’s what I tell people who ask whether a promising new medication means they can skip the behavioral piece: medication gets you to the starting line, but you still have to run the race. That framing, which shows up consistently in expert commentary around Simtriyo’s approval, isn’t a platitude. It reflects something well-documented in the research. Medication can reduce impulsivity and sharpen attention. It cannot teach organization systems, repair relationships that ADHD behavior has strained, build the metacognitive habits that make executive function actually work in a real life, or help someone understand why they’ve struggled for years and thought it was a character flaw.
Behavioral therapies for ADHD, particularly Cognitive Behavioral Therapy adapted for ADHD and skills-based coaching, do that work. They’re slow. They require repetition. And they work considerably better when a person’s neurological symptoms are also being treated effectively. A medication that works better for more people, including those with anxiety, doesn’t make therapy redundant. It potentially makes therapy more accessible. If someone could never sit still enough in session to retain what was being worked on, a more effective medication might be exactly what allows the therapeutic work to actually land.
What This Means If You’re Currently in Treatment
If you’re already working with a psychiatrist and a therapist, this probably doesn’t change your immediate plan. Simtriyo isn’t available yet. But it’s worth having a conversation with your prescriber now if stimulants haven’t been a good fit, if anxiety and ADHD are both in the picture, or if you’ve felt like the current options weren’t quite right. Your prescriber will be watching the DEA scheduling decision and can give you a realistic timeline.
The comparison below might help clarify where Simtriyo sits relative to the major existing categories:
| Medication Type | Example Drugs | Neurotransmitters Targeted | Schedule | Comorbid Anxiety Fit |
|---|---|---|---|---|
| Stimulant (amphetamine) | Adderall, Vyvanse | Dopamine, Norepinephrine | Schedule II | Often complicated |
| Stimulant (methylphenidate) | Ritalin, Concerta | Dopamine, Norepinephrine | Schedule II | Often complicated |
| Non-stimulant SNRI | Strattera | Norepinephrine | Schedule IV | Generally better |
| NDSRI (new class) | Simtriyo (centanafadine) | Dopamine, Norepinephrine, Serotonin | Pending DEA | Early data promising |
If you’re not currently in treatment at all, and you’ve been self-managing or wondering if what you’re experiencing is even ADHD, this is actually a good moment to start the process. Not because Simtriyo is available, but because the evaluation and therapy work takes time regardless of what medication ultimately makes sense. Starting now means you’re ready.
Simtriyo isn’t a cure, and it won’t be right for everyone. But for a population that’s been working with the same basic pharmacological toolkit for decades, a genuinely new mechanism, one that may finally help people whose anxiety made stimulants difficult, is meaningful news. The therapy still matters. The relationship with your care team still matters. And now, for some people who felt like they were out of options, there may be one more worth considering.
Sources
- Otsuka US – Official FDA Approval Press Release (July 24, 2026)
- Psychiatric Times – A New Mechanism for ADHD: Centanafadine’s FDA Approval (Late July 2026)
- Healthline – FDA Approves New CNS Drug Simtriyo for Adults and Children (July 29, 2026)
- Fierce Pharma – FDA Approves Otsuka’s ADHD Drug Simtriyo (Late July 2026)
- Psychology Today – A New ADHD Medication Is Here. Read the Fine Print. (August 2026)
Photo: Pavel Danilyuk via Pexels
This article is for general informational purposes only and does not constitute mental health, medical, or clinical advice. If you are in crisis or experiencing a mental health emergency, please contact the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room. Always consult a licensed mental health professional for care specific to your needs.
Recommended Resources
Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.
- Feeling Good: The New Mood Therapy (~$14), The most clinically studied self-help book for depression, recommended by therapists worldwide as CBT-based self-treatment.
- Depression & Anxiety Therapy Journal (~$10), 8-week guided journal with trigger tracking and mood diary, mirrors the homework your therapist would assign between sessions.
